Aziyo Biologics, Inc. AZYO
1.49 0.00 (+0.00%)
Sep 6, 2023, 3:59 PM EDT
1.40 Day range 1.54
52-week range unavailable
Analyst view
Consensus: buy
Buy
Price target (mean) 12.50 +738.9% upside
Now 1.49
- Target (low)
- 12.00
- Target (mean)
- 12.50
- Target (high)
- 13.00
Ratings (-1m) 2 2 buy · 0 hold · 0 sell
- Strong buy0
- Buy2
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- 1 month ago 2
- 2 months ago 2
- 3 months ago 4
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.35 | -0.35 – -0.35 | -0.69 | +49.3% | 15.00M | +18.7% | 1 |
| Next quarter | -0.36 | -0.36 – -0.36 | -0.73 | +50.7% | 14.90M | +20.5% | 1 |
| Current year | -1.60 | -1.60 – -1.60 | -2.38 | +32.8% | 58.80M | +19.5% | 1 |
| Next year | -0.88 | -0.88 – -0.88 | -1.60 | +45.0% | 72.00M | +22.4% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 12, 2023 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Nov 16, 2022 | Truist Securities | Maintained | — | Buy |
| Nov 15, 2022 | Piper Sandler | Maintained | — | Overweight |
| Mar 4, 2022 | Cowen & Co. | Maintained | — | Outperform |
| Nov 2, 2020 | Truist Securities | Initiated | — | Buy |
| Nov 2, 2020 | Cowen & Co. | Initiated | — | Outperform |
| Nov 2, 2020 | Cantor Fitzgerald | Initiated | — | Overweight |
| Nov 2, 2020 | Piper Sandler | Initiated | — | Overweight |